

Adaptimmune Therapeutics PLC

Form 3

January 04, 2016

FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â Tayton-Martin Helena Katrina

(Last)

(First)

(Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

01/01/2016

3. Issuer Name **and** Ticker or Trading Symbol
Adaptimmune Therapeutics PLC [ADAP]4. Relationship of Reporting
Person(s) to Issuer5. If Amendment, Date Original
Filed(Month/Day/Year)BROCK HOUSE,
SHEEPDROVE, LAMBOURN

(Street)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other
(give title below) (specify below)

Chief Operating Officer

6. Individual or Joint/Group
Filing(Check Applicable Line)☒ Form filed by One Reporting
Person☐ Form filed by More than One
Reporting PersonHUNGERFORD,Â X0Â RG17
7XA

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)Ordinary Shares with a nominal value of
GBP0.001 per share

1,815,000

D Â

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and
Expiration Date
(Month/Day/Year)3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)4. Conversion
or Exercise
Price of
Derivative5. Ownership
Form of
Derivative
Security:6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

Edgar Filing: Adaptimmune Therapeutics PLC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Option to purchase Ordinary Shares	Â <u>(1)</u>	01/25/2022	Ordinary Shares	192,500	\$ 0.1671 <u>(5)</u>	D	Â
Option to purchase Ordinary Shares	Â <u>(2)</u>	01/01/2023	Ordinary Shares	742,500	\$ 0.1671 <u>(6)</u>	D	Â
Option to purchase Ordinary Shares	Â <u>(3)</u>	04/14/2024	Ordinary Shares	850,000	\$ 0.1671 <u>(7)</u>	D	Â
Option to purchase Ordinary Shares	Â <u>(4)</u>	12/19/2024	Ordinary Shares	1,750,000	\$ 0.5308 <u>(8)</u>	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Tayton-Martin Helena Katrina BROCK HOUSE, SHEEPDROVE, LAMBOURN HUNGERFORD,Â X0Â RG17 7XA	Â	Â	Â Chief Operating Officer	Â

Signatures

/s/ Helen Katrina Tayton-Martin Name: Helen Katrina
Tayton-Martin

01/04/2016

 Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Currently exercisable as to 144,300 Ordinary Shares and will be exercisable as to 48,200 Ordinary Shares on January 25, 2016.

(2) Currently exercisable as to 694,500 Ordinary Shares and will be exercisable as to 48,000 Ordinary Shares on January 1, 2017.

(3) Currently exercisable as to 212,500 Ordinary Shares and will be exercisable as to the remainder ratably in annual installments on the fourteenth of April from April 14, 2016 through April 14, 2018.

(4) Exercisable as to 437,500 Ordinary Shares on December 19, 2015 and will be exercisable as to the remainder in monthly installments of 36,400 Ordinary Shares on the nineteenth of each month from January 19, 2016 through November 19, 2018, and in one installment of 38,500 Ordinary Shares on December 19, 2018.

(5) The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

(6) The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

(7) The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

(8) The exercise price was converted from GBP0.3557 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of

Edgar Filing: Adaptimmune Therapeutics PLC - Form 3

grant or of exercise.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.